This website uses cookies
Read our Privacy policy and Terms of use for more information.
Long Form Content
Jun 28, 2024
•
9 min read
Novo Nordisk buys 2seventy bio's hemophilia A asset, worm-derived therapies raise $16M, Abbvie buys Celsius Therapeutics for $250M, Kite Pharma to evaluate Cellares' cell therapy manufacturing platform, and Merck, Daiichi Sankyo's lung cancer mAb hit with FDA CRL
Jun 27, 2024
Novo Nordisk's Wegovy lands China NMPA approval, big DNA edits without CRISPR, Curie.Bio raises $380M VC fund, SK Bioscience buys IDK Biologika controlling stake, and Novo Nordisk's $816M Ph3 oof
Jun 26, 2024
Otsuka and Lundbeck’s PTSD sNDA filing accepted, Exsilio launches with $82M and big name investors, Zealand Pharma ups equity offering to $1B, Eli Lilly & OpenAI sign an antibiotic drug discovery pact, and Abbvie's Parkinson's med gets hit with a CRL
Jun 25, 2024
10 min read
Alnylam’s slam dunk Ph3 heart disease data, Pfizer tapped to supply RSV vaccine to the UK, Novo Nordisk shares detailed hemophilia A Ph3 data, Novo Nordisk earmarks $4.1B for NC manufacturing plant, and Merck KGaA cuts a Ph3 cancer trial short
Jun 24, 2024
8 min read
BMS & Takeda both land colorectal cancer approvals, don't doze on Eli Lilly's sleep apnea data, Tectonic goes IPO via reverse merger, Vertex signs reimbursement deal with NHS, while Ginkgo Bioworks cuts 150+ jobs
Jun 22, 2024
🧬 Winners, Losers, and Upcoming Earnings Calls
Jun 21, 2024
11 min read
Sapreta Therapeutics lands key DMD label expansion, Gilead's twice-yearly HIV prevention med scores 100% efficacy, iOnctura raises $86M, Takeda drops $230M on a facility expansion, and Bora makes US-based sterile manufacturing moves
Jun 19, 2024
GSK has a double Ph3 win, Marea Therapeutics launches with $190M to go after remnant cholesterol, Hikma buys multiple assets and sites from Xeliia Pharmaceuticals, and Sanofi and Roche both sign big drug development partnership
Jun 18, 2024
AstraZeneca & Merck both land FDA approvals for endometrial cancer, Takeda's epilepsy bet is up in flames, Merck lands a historic vaccine approval, and a BioNTech and MediLink Therapeutics ADC gets an FDA partial hold
Jun 17, 2024
Vertex releases positive long term gene therapy data, Vaxart lands a big BARDA contract, AI drug discovery debuts on Hong Kong stock exchange, Kyverna has a rough week due to autoimmune data and 100% of something for two cancer biotechs
Jun 15, 2024
Jun 14, 2024
Pfizer's DMD hopes shattered in Ph3 (while also planning for 8 blockbusters by 2030), while JP Morgan closes $500M biotech fund, a new antibody player launches with $168M, and Eli Lilly gets an upgrade (from accelerated to full approval)
